Other Track AgendasEnabling Genomic Technologies | Screening Asia |
Thursday, 11 September 201408:00 | Registration | | High Content Assay Discovery |
| | 09:00 | | Keynote Presentation Novel Medicines for Unmet Medical Needs - Translational R&D in Singapore Alex Matter, CEO, Experimental Therapeutics Centre & D3 A*STAR, Singapore
ETC has assembled all the technologies that are needed to perform state-of-the-art drug discovery. The principle is to form a partnership with a premier academic group working on a set of well-defined, validated targets. The goal is to discover novel, attractive and feasible Preclinical Development Candidates.
Subsequently, a complementary facility (D3) will take up such projects and bring them through preclinical development that will enable to reach an IND (CTC).
Such a drug candidate can then enter early clinical trials, to reach a Proof-of-Concept (PoC) that is based on evidence of tolerability, plausible pharmacokinetics and biomarker evidence of attractive pharmacodynamics. |
| 10:00 | Target-mechanism based whole cell screen for mycobacterial proteome disruptors Thomas Dick, Associate Professor, National University of Singapore, Singapore
| 10:30 | Coffee Break and Networking in Exhibition Area | 11:15 | High Content Assays Measuring Human Brain Pericyte Biology Mike Dragunow, Professor of Pharmacology, Auckland University, New Zealand
Brain pericytes are perivascular cells thought to play diverse roles in brain physiology and pathology including regulating blood-brain barrier integrity and brain capillary function, and acting as neural stem cells. Pericytes have been implicated in BBB leakage, neuroinflammation and scar formation, suggesting that they are important targets for the development of CNS acting drugs. We have developed high content assays to measure various features of human brain pericytes for drug screening purposes to identify novel molecules regulating pericyte function. | 11:45 | Phenotypic Screening of Cellular Organelle Function Robin Ketteler, Group Leader/Manager, University College London, United Kingdom
I will present an overview of two phenotypic screens that study cell biology processes in a large-scale screening setup.
First, I will present our results on screening for modulators of autophagy comparing a luciferase-based and an image-based assay.
Next, I will discuss data from our high-content analysis of secretory granule function in endothelial cells. | 12:15 | Lunch Break and Poster Session | 13:45 | 3D Model Systems John Watson, Director, Promega Corporation, United States of America
| | 3D Cellular Model Systems |
| | 14:15 | Scaffold- and Spheroid-based 3D Cell Culture Methods for Applications in Oncology and Toxicology Joy Hu, Technical Specialist, BioTek Instruments (Taiwan), Ltd., Taiwan
Automated methods for the preparation and execution of 3D cell culture methods using both scaffold- and spheroid-based methods will be presented.
Case studies in oncology and toxicology will be used as examples. | 14:45 | Coffee Break and Networking in Exhibition Area | 15:15 | Translational, robust 3D model systems for efficacy screening Jan Lichtenberg, CEO and Co-Founder, InSphero AG, Switzerland
Two key parameters assure high-quality screening data: valuable biological content and robust statistical relevance.
While three-dimensional (3D) cell models are widely recognized for their high level of organotypic morphology and functionality, well-to-well and batch-to-batch variations have been an obstacle in the past to translate this technology into standard screening processes.
In this presentation we illustrate how scaffold-free 3D microtissues obtained by an automated hanging-drop method yield highly uniform and organotypic cell models for screening in oncology and diabetes research. | 15:45 | Developing novel three dimensional cell culture platform for different testing purposes towards investigative biology Giridharan Periyasamy, Manager, Genome Institute of Singapore, Singapore
| 16:15 | Tour of the GIS High-throughput Cell Biology Centre (GIS-HTCB) | 17:30 | End of Day One |
Friday, 12 September 201408:00 | Registration | | Target-based Discovery |
| | 09:00 | | Keynote Presentation Regulating Wnts at the source David Virshup, Professor and Director, Duke-NUS Graduate Medical School Singapore, Singapore
Regulation of Wnt secretion is a promising new approach to the treatment of Wnt-high diseases. We have developed novel inhibitors of the Wnt modifying enzyme PORCN. These agents show significant activity in carefully selected preclinical models. There is a surprising lack of toxicity at therapeutically active doses. PORCN inhibitors represent a potential new therapy for cancer and other disorders. |
| 10:00 | Monitoring Adenine Nucleotide levels to assess cellular metabolic changes in response to environmental insults and altered metabolic status Said Goueli, Senior Research Fellow, Promega Corporation, United States of America
| 10:30 | Coffee Break and Networking in Exhibition Area | 11:15 | A kinase feedback loop controls RAS-driven, autophagy-dependent cancers Jit Kong Cheong , Instructor , Duke-NUS Graduate Medical School , Singapore
| 11:45 | Triphenylphosphonium analogs of the MET kinase inhibitor PHA 665752 : An approach to the targeting of mitochondrial MET in lung cancer cell lines Mei Lin Go, Associate Professor, National University of Singapore, Singapore
| 12:15 | Lunch Break and Poster Session | 13:45 | Discovery and validation of small molecules interfering with the BCL-2 driven apoptotic pathway Guillaume Lessene, Associate Professor, The Walter And Eliza Hall Institute of Medical Research, Australia
| 14:15 | Inhibitors for SMYD3, an epigenetic drug target Joma Joy, Group Leader, Experimental Therapeutics Centre (ETC), Singapore
| 14:45 | Coffee Break and Networking in Exhibition Area | 15:30 | PANEL DISCUSSION - Pros and Cons - CRISPR vs. RNAi / Is CRISPR going to wipe out RNAi? / 2D vs. 3D - What is the best model? / Cell-Based Assays vs. Cell-Free Assays | 17:00 | Closing Reception |
|